ANORO™ ELLIPTA™ Approved as First Once-Daily Dual Bronchodilator for the Treatment of COPD in the U.S.
December 20, 2013 |
GlaxoSmithKline and Theravance, Inc. announced on December 18, 2013 that the U.S. Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA™, a long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Anoro Ellipta is the first once-daily product approved in the U.S. that combines two long-acting bronchodilators in a single inhaler for the maintenance treatment of COPD.
“We are very pleased that Anoro Ellipta has become the first once-daily dual bronchodilator approved in the US for the treatment of COPD,” Rick E Winningham, Chief Executive Officer of Theravance, says. “This is a significant milestone for Theravance and GSK and is testament to our ongoing partnership and shared commitment to the development of respiratory medicines.”
To read the full press release, please click here.